Montelukast Asthmapharma (Montelukast)

Montelukast selectively blocks the cysteinyl leukotriene receptor CysLT1 on cells of the respiratory tract. By preventing leukotrienes from binding, it inhibits bronchoconstriction, vascular leakage and inflammatory cell recruitment, which together diminish airway edema, mucus production and hyper‑responsiveness, leading to improved breathing and reduced allergic symptoms.

The appropriate dose of Montelukast Asthmapharma is determined by the prescribing healthcare professional based on the patient’s age, weight, severity of disease and other clinical factors. The prescriber will specify the exact strength, frequency and duration of therapy on the prescription label, and patients should follow that guidance without alteration.

Safety data for montelukast in pregnancy and lactation are limited, and the medication should only be used if the potential benefit justifies any possible risk to the fetus or infant. Healthcare providers will evaluate the individual situation and may advise discontinuation or continuation based on current clinical guidelines and the patient’s condition.

To place an order, submit an enquiry on the product page at gnhindia.com, indicating the required quantity of Montelukast Asthmapharma. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting beta‑agonists. It is particularly useful for patients with allergic components, exercise‑induced bronchoconstriction, or those who prefer a once‑daily tablet. While it does not replace rescue bronchodilators, it can complement other controller therapies to achieve better overall asthma control.

Montelukast Asthmapharma should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture, light and excessive heat. Keep the product out of reach of children and do not use it after the expiration date printed on the label.

The medication is taken orally, usually as a tablet, with or without food as directed by the prescriber. Patients should swallow the tablet whole with a glass of water and follow the dosing schedule indicated on the prescription label, ensuring consistent daily intake for optimal therapeutic effect.

Although uncommon, serious adverse reactions can include severe allergic responses such as angioedema or anaphylaxis, neuropsychiatric events like depression or suicidal thoughts, and significant liver enzyme elevations. Patients should seek immediate medical attention if they experience symptoms such as rash, swelling, mood changes, jaundice or unexplained fatigue.

Montelukast Asthmapharma is contraindicated in individuals with known hypersensitivity to montelukast or any of the tablet’s excipients. It should also be avoided in patients requiring treatment for acute asthma attacks, as it does not provide rapid bronchodilation. Clinicians must assess each patient’s medical history before initiating therapy.